Medical Technologies

2017: PathoVax license on Chimeric L1/L2 Protein . .. Human Papillomavirus Vaccines

June 5, 2017

Kevin W. Chang, Ph.D.
Senior Technology Transfer Manager
NCI Technology Transfer Center
9609 Medical Center Drive,
RM 1E530 MSC 9702
Bethesda, MD 20892-9702
Telephone: (240)-276-6910;
Facsimile: (240)-276-5504;

Via Email: changke@mail.nih.gov.

RE: Prospective Grant of Exclusive Patent License: Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines

2017: AbPro license of patents for liver cancer

This was our comment on the license. See below for the June 8, 2017 NIH response, rejecting our requests for changes to the license to address pricing or transparency.


June 2, 2017

David A. Lambertson, Ph.D.,
Senior Licensing and Patenting Manager
NCI Technology Transfer Center
9609 Medical Center Drive
RM 1E530 MSC 9702
Bethesda, MD 20892-9702
Telephone: (240)-276-6467

Via Email: david.lambertson@nih.gov.

2017: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors

May 31, 2017

Sury Vepa, Ph.D., J.D.,
Senior Licensing and Patenting Manager
National Center for Advancing Translational Sciences'
NIH, 9800 Medical Center Drive, Rockville, MD 20850,
Phone: 301-217-9197,
Fax: 301-217-5736,
email sury.vepa@nih.gov.

RE: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors

Dear Dr. Vepa,

1. We propose there be language in the license to ensure that prices for products are “reasonable” -- the standard in 35 U.S.C. § 201(f) -- and do not discriminate against U.S. residents.

MedImmune

Founded in 1988.

January 29, 2004. Labs rush to cultivate bird flu vaccine Reverse genetics allows creation of weakened virus , Sabin Russell, Chronicle Medical Writer

Zika

On January 23, 2017, MSF file comments with the US Army in opposition to the grant of an exclusive license to patents on a new vaccine for the Zika Virus. A copy of the filing is on the MSF web page here.

2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc.

On May 18th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension Therapeutics, Inc. for development of an Anti-GPC3 Chimeric Antigen Receptor (CAR) Based on HN3 and YP7 for the Treatment of Human Cancers. Below are the comments KEI submitted to the NIH on June 2th, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 2nd, 2016

David A. Lambertson Ph.D.
Senior Licensing and Patenting Manager,
National Cancer Institute,

2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation

On May 19th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Etubics Corporation, for the development and commercialization of adeno-virus based cancer immunotherapy. Below are the comments KEI submitted to the NIH on June 3rd, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 3rd, 2016

Sabarni K. Chatterjee, Ph.D., M.B.A.
Senior Licensing and Patenting Manager,
NCI Technology Transfer Center,
9609 Medical Center Drive, RM 1E530 MSC 9702,

2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation

On May 18th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Chimeron Bio Corporation , Inc. for the development of Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, and Hepatocellular Cancer. Below are the comments KEI submitted to the NIH on June 2th, 2016.

Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses


June 2nd, 2016

Lauren Nguyen-Antczak, Ph.D., J.D.,
Sr. Licensing and Patenting Manager,

Syndicate content